Omega Therapeutics (OMGA) announced the appointment of Chris Schade to its Board of Directors. Schade brings over 30 years of experience across the biopharma industry to support the Company’s long-term growth objectives. Previously, Schade was President and Chief Executive Office of Aprea Therapeutics (APRE), where he has been serving as a member of the board since 2016 and as Chairman of the board since 2020.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMGA:
- Omega Therapeutics Appoints Chris Schade to its Board of Directors
- Omega Therapeutics to Participate in Two Upcoming Investor Conferences
- Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting